Syntegon reports 7% sales growth as pharma business drives the first-half 2026 results

GERMANY—Syntegon, a strategic technology partner to the pharmaceutical, biotechnology, and food industries, has recorded strong financial growth in the first half of 2026, supported by rising demand for pharmaceutical manufacturing technologies.

The company reported group sales of EUR 883 million (US$1.03 billion), representing a 7 percent increase from the same period in 2025.

Adjusted EBITDA rose 16 percent to EUR 148 million (US$172 million), while the adjusted EBITDA margin increased by 130 basis points to 16.8 percent.

Syntegon also recorded an order intake of EUR 964 million (US$1.12 billion).

Its book-to-bill ratio reached 1.09, while the order backlog rose to a record EUR 1.3 billion (US$1.52 billion), giving the company a substantial pipeline of future business.

Pharma leads growth

The pharmaceutical business was Syntegon’s strongest contributor to growth, with sales increasing 14 percent during the first half of 2026.

The company attributed the performance to continued investment in biologics and injectable medicines, as well as growing demand for flexible and highly automated production systems.

Demand remained particularly strong for aseptic fill and finish equipment and isolator-equipped production lines.

Syntegon said increasingly stringent regulatory requirements also supported demand for these technologies.

Pharma Solid, another part of the company’s pharmaceutical business, also recorded double-digit growth.

The increase reflected stronger demand for capsule filling technologies and the expansion of Syntegon’s granulation product portfolio.

Torsten Türling, CEO of Syntegon, said the results reflected the company’s strategy and its position in the pharmaceutical manufacturing market.

“Our Pharma business remains our strongest growth engine,” Türling said.

“We achieved major new customer wins and market share gains in the expanding biologics market globally and in the United States in particular.”

Strong demand across key markets

Syntegon said its customer-focused approach and lifecycle partner strategy helped it secure new business during the period.

The company’s new solutions contributed to several customer wins across the pharmaceutical and biotechnology sectors.

Europe remained an important market for the Pharma business, with demand holding firm during the first half of the year.

In Asia, Pharma sales increased substantially year on year as Syntegon expanded its presence in the growing biologics market and benefited from its operations in China.

The United States also recorded significant growth. Pharma order intake increased substantially as Syntegon continued to implement its focused growth strategy in the market.

Improved profitability

Syntegon’s financial performance also reflected stronger profitability. Adjusted EBITDA increased more than twice as quickly as sales, lifting the margin to 16.8 percent.

Eros Carletti, Syntegon’s CFO, attributed the improvement to stronger contributions from Pharma, tighter operational management, and better project execution.

“Our solid order book provides a strong foundation for continued profitable growth and cash generation,” Carletti said.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on LinkedIn for updates.